Abstract The phosphatidylinositol 3-kinase (PI3K)/protein kinase B (PKB/Akt)/mechanistic
target of rapamycin (mTOR) signaling pathway has been associated with several …

The present study reports the behavioral, electrophysiological, and neuropathological
effects of cannabidiol (CBD), a major non-psychotropic constituent of Cannabis sativa, in the …

Cannabidiol (CBD), the main nonpsychotomimetic compound from Cannabis sativa, inhibits
experimental seizures in animal models and alleviates certain types of intractable epilepsies …

Background Epilepsy is one of the most common brain disorder and, despite the possible
use of several therapeutic options, many patients continue to have seizures for their entire …

Background: Status epilepticus (SE) is a series of seizures that can lead to serious
neurological damages. Cannabidiol (CBD) is extracted from the cannabis plant, which has …

Background and Purpose A non‐psychoactive phytocannabinoid, cannabidiol (CBD), shows
promising results as an effective potential antiepileptic drug in some forms of refractory …

Epilepsy is a neurological disorder characterized by the presence of seizures and
neuropsychiatric comorbidities. Despite the number of antiepileptic drugs, one-third of …

Cannabidiol is a nonpsychoactive member of phytocannabinoids that produces various
pharmacological effects that are not mediated through putative CB1/CB2 cannabinoid …

Epilepsy is a chronic neurological disease characterized by recurrent epileptic seizures.
Studies have shown the complexity of epileptogenesis and ictogenesis, in which …

Cannabidiol (CBD) showed anticonvulsant action in several preclinical models and is
currently approved by regulatory agencies to treat childhood epilepsy syndromes. However …